Search
Paclitaxel Treatment Options
A collection of 2051 research studies where Paclitaxel is the interventional treatment. These studies are located in the United States . Paclitaxel is used for conditions such as Breast Cancer, Ovarian Cancer and Non-Small Cell Lung Cancer.
481 - 492 of 2051
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Therapy
Unique Treatment for High Blood Pressure
Worried about high blood pressure? Think beyond typical high blood pressure treatments.
People who may be candidates for this procedure:
• Are at least 18 years old
• Have been unable to manage their high blood pressure with medications or lifestyle changes alone¹
Learn about a safe and effective procedure that may help reduce high blood pressure. See if you qualify today.
¹ Kandzari DE, et al. J Am Coll Cardiol. Nov 7, 2023;82(19):1809-1823.
People who may be candidates for this procedure:
• Are at least 18 years old
• Have been unable to manage their high blood pressure with medications or lifestyle changes alone¹
Learn about a safe and effective procedure that may help reduce high blood pressure. See if you qualify today.
¹ Kandzari DE, et al. J Am Coll Cardiol. Nov 7, 2023;82(19):1809-1823.
Conditions:
High Blood Pressure
High Blood Pressure (& [Essential Hypertension])
High Blood Pressure (Hypertension).
Hypertension
Essential Hypertension
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Conditions:
Healthy
Healthy Volunteer Study
Featured Trial
Discover Clinical Trials In Your Area (Compensation Provided)
Recruiting
Clinical trials in your area are actively enrolling — and they compensate you for your time. Finding the right one has never been easier.
- Matched to trials in your zip code
- Compensation for time & travel
- Free or low-cost treatments available
- No experience or medical background needed
- Takes just 30 seconds to see if you qualify
- Matched to trials in your zip code
- Compensation for time & travel
- Free or low-cost treatments available
- No experience or medical background needed
- Takes just 30 seconds to see if you qualify
Conditions:
Healthy
Healthy Volunteers
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
Active Not Recruiting
The safety and efficacy of pembrolizumab plus the investigator's choice of chemotherapy will be assessed compared to placebo plus the investigator's choice of chemotherapy in the treatment of chemotherapy-candidate hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally recurrent inoperable or metastatic breast cancer.
The primary hypotheses are that the combination of pembrolizumab and chemotherapy is superior to placebo and chemotherapy in regards to P... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: University of Alabama at Birmingham-Medicine ( Site 0065), Birmingham, Alabama +255 locations
Conditions: Breast Neoplasms
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
Active Not Recruiting
This phase I/IB trial tests the safety, side effects, and best dose of ipatasertib in combination with paclitaxel and carboplatin in treating patients with stage III or IV epithelial ovarian cancer. Ipatasertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Paclitaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compou... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: UCSF Medical Center-Mission Bay, San Francisco, California +7 locations
Conditions: Fallopian Tube Endometrioid Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Unresectable Fallopian Tube Endometrioid Adenocarcinoma, Unresectable Fallopian Tube High Grade Serous Adenocarcinoma, Unresectable Ovarian Endometrioid Adenocarcinoma, Unresectable Ovarian High Grade Serous Adenocarcinoma, Unresectable Primary Peritoneal Endometrioid Adenocarcinoma, Unresectable Primary Peritoneal High Grade Serous Adenocarcinoma
A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment
Completed
The purpose of this study is to look at the efficacy and safety of Irinotecan liposome injection in combination with other approved drugs used for cancer therapy, namely 5 fluorouracil/leucovorin (5FU/LV) plus oxaliplatin compared to nab-paclitaxel + gemcitabine treatment in improving the overall survival of patients not previously treated for metastatic pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +199 locations
Conditions: Metastatic Adenocarcinoma of the Pancreas
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
Completed
This study is designed to explore the potential of the epigenetic agent RRx-001 to sensitize patients who previously received and now have failed a platinum based doublet regimen. RRx-001 is administered with autologous blood once weekly followed by or in combination with reintroduction of platinum-based doublet therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2025
Locations: Stanford University, Palo Alto, California +9 locations
Conditions: Small Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Neuroendocrine Tumors, Ovarian Epithelial Cancer
Combination of Serabelisib and Insulin Suppressing Diet with or Without Nab-paclitaxel in Subjects with Advanced Solid Tumors with PIK3CA Mutations
Active Not Recruiting
This study will evaluate the feasibility of optimizing the safety and tolerability of serabelisib (an investigational PI3K inhibitor) when combined with an ISD and with or without nab-paclitaxel with a goal of reducing side effects and enhancing anticancer activity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: University of Alabama, Birmingham, Alabama +16 locations
Conditions: Advanced Solid Tumor, PIK3CA Mutation, PTEN Loss of Function Mutation
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
Recruiting
The purpose of this study is to learn whether clinical response (the amount a tumor shrinks based on imaging or tumor measurements obtained by physical exam) predicts pathologic response (the amount of tumor remaining when surgery is performed) in participants with breast cancer who are receiving chemotherapy prior to surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Harris Health System - Smith Clinic, Houston, Texas +1 locations
Conditions: Breast Cancer, Breast Neoplasm, Breast Cancer Female, Breast Cancer Invasive, Breast Cancer Stage II, Breast Cancer Stage III, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Neoplasms, Estrogen Receptor-positive Breast Cancer
Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Active Not Recruiting
This clinical trial studies image-guided hypofractionated radiation therapy (RT) when given together with hypofractionated RT boost and combination chemotherapy in treating patients with stage II-III non-small cell lung cancer (NSCLC) that cannot be removed by surgery. RT uses high energy x-rays to kill tumor cells. Hypofractionated RT may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Jonsson Comprehensive Cancer Center, Los Angeles, California
Conditions: Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer
Active Not Recruiting
This is a single-arm, open-label, phase 2 study that will enroll 36 subjects, who have pathologically proven diagnosis of invasive breast cancer, clinical stage tumor 1-3 (cT1-T3), node 0-3 (cN0-N3), metastasis 0 (cM0), hormone receptor positive (HR+) (estrogen-receptor-positive (ER+) and/or progesterone-receptor-positive (PR+) human epidermal growth factor receptor 2 (HER2) negative or hormone receptor-negative (HR-) (estrogen-receptor-negative (ER-) and progesterone-receptor-negative (PR-) hum... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Froedtert Hospital & Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Invasive Breast Cancer
QUILT-3.088: NANT Pancreatic Cancer Vaccine
Withdrawn
QUILT-3.088 NANT Pancreatic Cancer Vaccine: Phase II Randomized Trial of the NANT Pancreatic Cancer Vaccine vs. Standard-of-Care as First- Line Treatment for Patients with Metastatic Pancreatic Cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Chan Soon-Shiong Institute for Medicine, El Segundo, California
Conditions: Metastatic Pancreatic Cancer
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
Withdrawn
This is a randomized phase 2 study to compare the efficacy of neoadjuvant, consolidation, and adjuvant immunotherapy (NANT NSCLC Combination Immunotherapy; experimental arm) to standard of care (surgery and adjuvant chemotherapy; control arm) in subjects with stage II-IIIa resectable NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Chan Soon-Shiong Institute for Medicine, El Segundo, California
Conditions: Non Small Cell Lung Cancer
QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine
Withdrawn
This is a randomized open-label phase 2 study to evaluate the efficacy and safety (as assessed by pCR) of the NANT Neoadjuvant TNBC Vaccine regimen (experimental arm) compared to the SoC dose-dense regimen of doxorubicin/cyclophosphamide followed by paclitaxel (control arm).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Chan Soon-Shiong Institute for Medicine, El Segundo, California
Conditions: Triple Negative Breast Cancer (TNBC)
Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)
Completed
The purpose of this study is to compare the efficacy of pembrolizumab + lenvatinib to chemotherapy in female participants with Stage III, IV, or recurrent endometrial carcinoma. It is hypothesized that the combination of pembrolizumab + lenvatinib will be superior to chemotherapy for progression-free survival (PFS) per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR). It is also hypothesized that the combination of pembrolizumab +... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: University of South Alabama, Mitchell Cancer Institute ( Site 0245), Mobile, Alabama +194 locations
Conditions: Endometrial Neoplasms
481 - 492 of 2051